Beyond Independent Shots on Goal: Risk Capacity, Synergy, and Concentration in Pharmaceutical R&D Portfolios

In the high-stakes world of pharmaceutical research, companies do not simply bet on a single new drug; they build portfolios, collections of different projects designed to keep the business alive and growing. Imagine a farmer planting seeds. A cautious farmer might scatter seeds across many different fields, hoping that if a drought hits one field, the others will still survive. A more aggressive farmer might plant all the seeds in one field, betting that a single, massive harvest will pay off handsomely, but risking total loss if that one field fails. In drug development, this choice plays out between spreading resources across many unrelated diseases versus focusing intensely on a single drug or a single biological mechanism to treat several different conditions. The first approach offers safety through variety, while the second offers the promise of efficiency, where shared knowledge and manufacturing can lower costs. However, the second approach carries a hidden danger: if the core science is flawed, every single project in that cluster fails at once.

The question facing modern drug developers is not just which strategy looks cheaper on paper, but which one a company can actually survive if things go wrong. A standard calculation used by these companies, known as expected net present value, simply adds up the average potential profit of all projects. This method often fails to see the difference between a portfolio that is likely to succeed and one that is likely to crash the company's finances. A new analysis by independent researcher Michael Robert Doane moves beyond these simple averages to map out the true risks of concentrating drug development. By simulating thousands of different scenarios, the study reveals exactly how much money a company must save to justify the danger of putting all its eggs in one basket, and how much value is lost when a company ignores the fact that its own drugs might compete with each other for sales.

Doane's work focuses on three distinct ways a company might organize six drug development programs. The first is the diversified approach, where each program targets a completely different disease or biological pathway, ensuring that a failure in one does not affect the others. The second is the "pipeline in a pill" strategy, where all six programs are different uses for the exact same drug molecule. The third is the "multiple shots on goal" approach, where several different drugs are developed to target the same biological mechanism. While the first strategy spreads risk, the latter two offer the potential for synergy, where sharing data, manufacturing, and clinical trials can drastically reduce costs. The study uses powerful computer simulations to test these strategies, not just looking at the average outcome, but specifically at the worst-case scenarios. It asks a critical question: if a company has a limited amount of cash, can it afford to survive a string of bad luck where all its concentrated projects fail simultaneously?

The simulations show that while concentrating efforts does not change the average expected profit, it dramatically increases the risk of a catastrophic financial loss. When six programs are tied to a single drug or mechanism, they tend to succeed or fail together. In the study's central scenario, a concentrated strategy without any cost savings was just as likely to result in zero successful drugs as it was to result in a massive windfall, but the downside was far more severe. The risk of running out of money, a situation known as a liquidity breach, jumped significantly. For a company with a moderate amount of cash, the concentrated strategy was so risky that it was impossible to justify, even if the company managed to cut research costs by thirty percent. Only for companies with very large financial reserves did the concentrated approach become a viable option, and even then, it required specific conditions to be met.

To make a concentrated strategy work, the savings must be substantial. In the most balanced scenario tested, a company needed to save at least twenty percent on the research and development costs for the additional drug uses to make the concentrated plan as attractive as the diversified one. When the researchers tested this against a thousand different sets of hypothetical drug programs, they found that the required savings varied widely. In about seventeen percent of the cases, no amount of savings up to thirty percent was enough to make the concentrated strategy safe; the risk of failure was simply too high for the company's financial limits. On average, the study found that a company needed to save twenty-three percent on costs to justify the concentration. This means that the promise of efficiency must be very real and very large to offset the danger of a total collapse.

The study also examined the timing of these decisions, comparing a strategy where all trials start at once versus one where trials are staged, waiting for the first success before starting the next. Staging trials saves money in the short term because the company does not spend cash on projects that might fail early. However, this delay comes at a steep price. By waiting to start the later trials, the successful drugs launch later, meaning they have fewer years to make money before their patent protection expires. The simulations showed that while staging reduced development costs, it destroyed nearly half a billion dollars in potential value compared to starting everything in parallel. The company saved money on the way up but lost far more on the way down, proving that saving cash today is not always the same as creating value for tomorrow.

Another critical finding concerns the hidden competition between a company's own products. When a company develops multiple drugs for similar conditions, these drugs can end up competing with each other, eating into the sales of the very products they were meant to support. The study calculated the cost of ignoring this reality. If a company assumes its drugs will not compete with each other, but they actually do, the financial regret can be severe. In the simulations, ignoring a twenty-five percent overlap in sales led to a median loss of fifty-nine million dollars in expected value. In the worst cases, this error cost the company up to one hundred and sixty million dollars. This suggests that the mathematical models used to decide which drugs to develop must account for the fact that a new drug might cannibalize the revenue of an existing one.

The research also looked at how many drug projects a company needs to start to ensure it gets at least two successful drugs to market. Because concentrated strategies carry a higher risk of total failure, a company needs to start more projects to achieve the same level of reliability. To have an eighty percent chance of launching at least two drugs, a diversified portfolio needed to start nineteen projects. A concentrated "pipeline in a pill" strategy needed to start twenty-five projects. This difference highlights that concentration is not just about efficiency; it is a gamble that requires a larger safety net. The study concludes that while concentrating drug development can be a smart move for well-funded companies with deep pockets, it is a dangerous path for those with limited resources. The decision cannot be made based on average profits alone; it requires a clear understanding of how much risk the company can absorb and how much real savings are needed to make the gamble worth it.